Ipamorelin + CJC-1295: The Gold Standard

Ipamorelin is a pentapeptide growth hormone releasing peptide (GHRP) that stimulates GH release by activating the ghrelin receptor in the pituitary gland. What sets Ipamorelin apart from older GHRPs like GHRP-6 and GHRP-2 is its remarkable selectivity. It produces a strong, clean GH pulse without significantly raising cortisol, prolactin, or appetite (a common side effect of ghrelin receptor activation). This selectivity makes it the most commonly recommended GHRP for long-term use. Typical dosing is 200-300mcg per injection, administered 1-3 times daily.

CJC-1295 is a modified version of GHRH (the natural hormone that tells your pituitary to release GH). It comes in two forms: with DAC (Drug Affinity Complex) and without DAC (also called Mod GRF 1-29). The DAC version has a dramatically extended half-life of approximately 8 days, providing a sustained elevation of baseline GH. The non-DAC version (Mod GRF 1-29) has a short half-life similar to natural GHRH, producing acute GH pulses. Most practitioners prefer the non-DAC version (Mod GRF 1-29) for combination use with Ipamorelin because it better preserves the natural pulsatile release pattern.

The Ipamorelin + CJC-1295 (no DAC) combination is considered the gold standard GH secretagogue stack. These two peptides work through complementary mechanisms: CJC-1295 stimulates GHRH receptors (the gas pedal) while Ipamorelin stimulates ghrelin receptors (an independent GH release trigger). Together, they produce a GH pulse significantly larger than either peptide alone. Standard dosing is 100-300mcg of each, administered together via subcutaneous injection. The most important timing consideration is taking these on a completely empty stomach, as food intake (particularly carbohydrates and fats) blunts GH release by triggering somatostatin.